Matthew J Smith1,2, Eva C Alden2, Amy A Herrold2,3, Andrea Roberts4, Dan Stern5, Joseph Jones6, Allan Barnes7, Kailyn P O'Connor2, Marilyn A Huestis7,8, Hans C Breiter2. 1. School of Social Work, University of Michigan, Ann Arbor, Michigan. 2. Warren Wright Adolescent Center, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 3. Edward Hines Jr. Veterans Affairs Hospital, Research Service, Hines, Illinois. 4. Department of Psychology, University of Michigan, Ann Arbor, Michigan. 5. Department of Neuroscience, University of California-San Diego, La Jolla, California. 6. United States Drug Testing Laboratories, Des Plaines, Illinois. 7. Chemistry and Drug Metabolism, National Institute on Drug Abuse, Rockville, Maryland. 8. University of Maryland School of Medicine, Baltimore, Maryland.
Abstract
OBJECTIVE: Research typically characterizes cannabis use by self-report of cannabis intake frequency. In an effort to better understand relationships between measures of cannabis use, we evaluated if Δ-9-tetrahydrocannabinol (THC) and metabolite concentrations (biometrics) were associated with a calibrated timeline followback (TLFB) assessment of cannabis use. METHOD: Participants were 35 young adult male cannabis users who completed a calibrated TLFB measure of cannabis use over the past 30 days, including time of last use. The calibration required participants handling four plastic bags of a cannabis substitute (0.25, 0.5, 1.0, and 3.5 grams) to quantify cannabis consumed. Participants provided blood and urine samples for analysis of THC and metabolites, at two independent laboratories. Participants abstained from cannabis use on the day of sample collection. We tested Pearson correlations between the calibrated TLFB measures and cannabis biometrics. RESULTS: Strong correlations were seen between urine and blood biometrics (all r > .73, all p < .001). TLFB measures of times of use and grams of cannabis consumed were significantly related to each biometric, including urine 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) and blood THC, 11-hydroxy-THC (11-OH-THC), THCCOOH, THCCOOH-glucuronide (times of use: r > .48-.61, all p < .05; grams: r > .40-.49, all p < .05). CONCLUSIONS: This study extends prior work to show TLFB methods significantly relate to an extended array of cannabis biometrics. The calibration of cannabis intake in grams was associated with each biometric, although the simple TLFB measure of times of use produced the strongest relationships with all five biometrics. These findings suggest that combined self-report and biometric data together convey the complexity of cannabis use, but allow that either the use of calibrated TLFB measures or biometrics may be sufficient for assessment of cannabis use in research.
OBJECTIVE: Research typically characterizes cannabis use by self-report of cannabis intake frequency. In an effort to better understand relationships between measures of cannabis use, we evaluated if Δ-9-tetrahydrocannabinol (THC) and metabolite concentrations (biometrics) were associated with a calibrated timeline followback (TLFB) assessment of cannabis use. METHOD:Participants were 35 young adult male cannabis users who completed a calibrated TLFB measure of cannabis use over the past 30 days, including time of last use. The calibration required participants handling four plastic bags of a cannabis substitute (0.25, 0.5, 1.0, and 3.5 grams) to quantify cannabis consumed. Participants provided blood and urine samples for analysis of THC and metabolites, at two independent laboratories. Participants abstained from cannabis use on the day of sample collection. We tested Pearson correlations between the calibrated TLFB measures and cannabis biometrics. RESULTS: Strong correlations were seen between urine and blood biometrics (all r > .73, all p < .001). TLFB measures of times of use and grams of cannabis consumed were significantly related to each biometric, including urine 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) and blood THC, 11-hydroxy-THC (11-OH-THC), THCCOOH, THCCOOH-glucuronide (times of use: r > .48-.61, all p < .05; grams: r > .40-.49, all p < .05). CONCLUSIONS: This study extends prior work to show TLFB methods significantly relate to an extended array of cannabis biometrics. The calibration of cannabis intake in grams was associated with each biometric, although the simple TLFB measure of times of use produced the strongest relationships with all five biometrics. These findings suggest that combined self-report and biometric data together convey the complexity of cannabis use, but allow that either the use of calibrated TLFB measures or biometrics may be sufficient for assessment of cannabis use in research.
Authors: E L Karschner; W D Darwin; R P McMahon; F Liu; S Wright; R S Goodwin; M A Huestis Journal: Clin Pharmacol Ther Date: 2011-02-02 Impact factor: 6.875
Authors: Nathalie A Desrosiers; Dayong Lee; Karl B Scheidweiler; Marta Concheiro-Guisan; David A Gorelick; Marilyn A Huestis Journal: Anal Bioanal Chem Date: 2013-12-01 Impact factor: 4.142
Authors: Krista Lisdahl Medina; Tim McQueeny; Bonnie J Nagel; Karen L Hanson; Tony T Yang; Susan F Tapert Journal: Addict Biol Date: 2009-07-24 Impact factor: 4.280
Authors: Karl B Scheidweiler; David M Schwope; Erin L Karschner; Nathalie A Desrosiers; David A Gorelick; Marilyn A Huestis Journal: Clin Chem Date: 2013-03-21 Impact factor: 8.327
Authors: Susan F Tapert; Alecia D Schweinsburg; Sean P A Drummond; Martin P Paulus; Sandra A Brown; Tony T Yang; Lawrence R Frank Journal: Psychopharmacology (Berl) Date: 2007-06-09 Impact factor: 4.530
Authors: M Camille Hoffman; Sharon K Hunter; Angelo D'Alessandro; Kathleen Noonan; Anna Wyrwa; Robert Freedman Journal: Psychol Med Date: 2019-07-31 Impact factor: 7.723
Authors: Cristina Sempio; Marilyn A Huestis; Susan K Mikulich-Gilbertson; Jost Klawitter; Uwe Christians; Thomas K Henthorn Journal: Br J Clin Pharmacol Date: 2020-01-20 Impact factor: 4.335
Authors: Katina C Calakos; Heather Liu; Yihuan Lu; Jon Mikael Anderson; David Matuskey; Nabeel Nabulsi; Yunpeng Ye; Patrick D Skosnik; Deepak Cyril D'Souza; Evan D Morris; Kelly P Cosgrove; Ansel T Hillmer Journal: Drug Alcohol Depend Date: 2021-07-29 Impact factor: 4.852
Authors: Cristina Sempio; L Cinnamon Bidwell; Kent Hutchison; Marilyn A Huestis; Jost Klawitter; Uwe Christians; Thomas K Henthorn Journal: Ther Drug Monit Date: 2021-08-01 Impact factor: 3.118
Authors: Natasha E Wade; Rachel Baca; Kelly E Courtney; Connor J McCabe; M Alejandra Infante; Marilyn A Huestis; Joanna Jacobus Journal: J Int Neuropsychol Soc Date: 2021-07 Impact factor: 2.892